Physician profile
Jonathan A White
NPI 1598893224
$2,498.02
in general payments reported to CMS, 2019-2025
25 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $932 · 2020: $147 · 2021: $19.40 · 2022: $131 · 2023: $213 · 2024: $356 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $909.17 | 2019-2025 | Linzess, Viberzi, Creon |
| Covidien LP | $241.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $232.15 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.93 | 2019-2024 | Trulance |
| Ardelyx, INC. | $159.34 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $139.64 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $74.36 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $56.63 | 2024-2025 | Resmetirom, Rezdiffra |
| Allergan, INC. | $56.52 | 2019 | |
| Pfizer INC. | $55.04 | 2023-2025 | |
| Janssen Biotech, INC. | $51.20 | 2019 | |
| Ucb, INC. | $46.28 | 2019 | |
| Lilly USA, LLC | $44.77 | 2025 | Omvoh |
| Celgene Corporation | $40.70 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $33.76 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.30 | 2025 | Uplizna |
| Genzyme Corporation | $19.49 | 2024 | |
| Intra-Sana Laboratories | $18.17 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Aimmune Therapeutics, INC. | $17.41 | 2025 | Zenpep |
| E.R. Squibb & Sons, L.L.C. | $16.14 | 2022 | |
| Merck Sharp & Dohme LLC | $15.02 | 2019 | |
| Redhill Biopharma INC. | $14.45 | 2023 | Aemcolo, Movantik, Talicia |
| Qol Medical, LLC | $14.23 | 2019 | |
| Daiichi Sankyo INC. | $13.85 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.